Alexandria Real Estate Equities, Inc. (ARE)
Alexandria Real Estate Equities, Inc. (ARE) is a real estate investment trust (REIT) specializing in the ownership, operation, and development of innovative office, laboratory, and technology campuses primarily located in major life science hubs across the United States. The company focuses on properties that support the growth of the life sciences industry, including biotech, pharmaceutical, and research firms. Founded in 1994, Alexandria REIT is known for its high-quality, sustainable properties and strategic emphasis on tenants engaged in scientific and health-related research.
Dividend History
Investors can expect a dividend payout of $1.32 per share, scheduled to be distributed in 25 days on October 15, 2025
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| October 15, 2025 | $1.32 | 2025-09-30 | 2025-09-30 |
| July 15, 2025 | $1.32 | 2025-06-30 | 2025-06-30 |
| April 15, 2025 | $1.32 | 2025-03-31 | 2025-03-31 |
| January 15, 2025 | $1.32 | 2024-12-31 | 2024-12-31 |
| October 15, 2024 | $1.30 | 2024-09-30 | 2024-09-30 |
Dividends Summary
- Alexandria Real Estate Equities, Inc. has issued 88 dividend payments over the past 21 years
- The most recent dividend was paid 67 days ago, on July 15, 2025
- The highest dividend payed out to investors during this period was $1.32 per share
- The average dividend paid during this period was $0.83 per share.
Company News
Alexandria Real Estate, a healthcare-focused REIT, offers a 6.2% dividend yield and provides stable rental income from research properties across the healthcare sector, despite recent occupancy challenges.
Alexandria Real Estate has experienced significant stock price decline due to post-pandemic biotech funding normalization, with sales growth decelerating and potential funding challenges. Despite current uncertainties, the company remains financially stable with a well-covered dividend.
Alexandria Real Estate Equities, Inc. has declared a quarterly cash dividend of $1.32 per common share for the second quarter of 2025, maintaining the dividend at its current level to provide the company with additional liquidity and strengthen its balance sheet.
Galatea Bio, a leader in AI-driven genomic research and clinical genetic testing, has secured $25 million in funding to expand its Biobank of the Americas into the Galatea Global Biobank, a landmark initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry. This will unlock new insights into human health and enable precision healthcare on a global scale.
Robust demand for Alexandria's (ARE) high-quality life science and lab office properties in key markets, healthy operating performance and expansion efforts bode well for long-term growth.
